{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:09:42Z","timestamp":1777500582263,"version":"3.51.4"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["NeuroToxicology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.neuro.2016.12.008","type":"journal-article","created":{"date-parts":[[2016,12,30]],"date-time":"2016-12-30T17:47:37Z","timestamp":1483120057000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["BoNT\/AB hybrid maintains similar duration of paresis as BoNT\/A wild-type in murine running wheel assay"],"prefix":"10.1016","volume":"59","author":[{"given":"Anna","family":"Kutschenko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Christine","family":"Reinert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadja","family":"Krez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Liebetanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Rummel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuro.2016.12.008_bib0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0041-0101(01)00101-5","article-title":"A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice","volume":"39","author":"Aoki","year":"2001","journal-title":"Toxicon"},{"key":"10.1016\/j.neuro.2016.12.008_bib0010","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature12732","article-title":"Structural basis for recognition of synaptic vesicle protein 2C by botulinum neurotoxin A","volume":"505","author":"Benoit","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.neuro.2016.12.008_bib0015","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.3390\/toxins7124855","article-title":"Botulinum neurotoxins: qualitative and quantitative analysis using the mouse phrenic nerve hemidiaphragm assay (MPN)","volume":"7","author":"Bigalke","year":"2015","journal-title":"Toxins. (Basel)"},{"key":"10.1016\/j.neuro.2016.12.008_bib0020","first-page":"307","article-title":"Botulinum toxin: application, safety, and limitations","volume":"364","author":"Bigalke","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.neuro.2016.12.008_bib0025","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1111\/j.1471-4159.2009.06093.x","article-title":"Cell entry strategy of clostridial neurotoxins","volume":"109","author":"Binz","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuro.2016.12.008_bib0030","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.toxicon.2008.12.027","article-title":"Receptor and substrate interactions of clostridial neurotoxins","volume":"54","author":"Brunger","year":"2009","journal-title":"Toxicon"},{"key":"10.1016\/j.neuro.2016.12.008_bib0035","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1113\/jphysiol.1949.sp004364","article-title":"The action of botulinum toxin on the neuromuscular junction","volume":"109","author":"Burgen","year":"1949","journal-title":"J. Physiol."},{"key":"10.1016\/j.neuro.2016.12.008_bib0040","first-page":"287","article-title":"Transforming the domain structure of botulinum neurotoxins into novel therapeutics","volume":"364","author":"Chaddock","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.neuro.2016.12.008_bib0045","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","article-title":"Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia","volume":"65","author":"Comella","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.neuro.2016.12.008_bib0050","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1083\/jcb.200305098","article-title":"Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells","volume":"162","author":"Dong","year":"2003","journal-title":"J. Cell. Biol."},{"key":"10.1016\/j.neuro.2016.12.008_bib0055","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1123654","article-title":"SV2 is the protein receptor for botulinum neurotoxin A","volume":"312","author":"Dong","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.neuro.2016.12.008_bib0060","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s00415-002-0929-4","article-title":"Botulinum toxin type B for treatment of axillar hyperhidrosis","volume":"249","author":"Dressler","year":"2002","journal-title":"J. Neurol."},{"key":"10.1016\/j.neuro.2016.12.008_bib0065","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000064953","article-title":"Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy","volume":"48","author":"Dressler","year":"2002","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.neuro.2016.12.008_bib0070","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1074\/jbc.M209821200","article-title":"Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons","volume":"278","author":"Foran","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuro.2016.12.008_bib0075","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/MMBR.46.1.86-94.1982","article-title":"Bacterial toxins: a table of lethal amounts","volume":"46","author":"Gill","year":"1982","journal-title":"Microbiol. Rev."},{"key":"10.1016\/j.neuro.2016.12.008_bib0080","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.toxicon.2013.06.010","article-title":"Exchanging the minimal cell binding fragments of tetanus neurotoxin in botulinum neurotoxin A and B impacts their toxicity at the neuromuscular junction and central neurons","volume":"75","author":"H\u00f6ltje","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.neuro.2016.12.008_bib0085","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF00500299","article-title":"Tetanus toxin blocks the neuromuscular transmission in vitro like botulinum A toxin","volume":"311","author":"Habermann","year":"1980","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.neuro.2016.12.008_bib0090","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.neuroscience.2005.12.029","article-title":"Recovery from botulinum neurotoxin poisoning in vivo","volume":"139","author":"Keller","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuro.2016.12.008_bib0095","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nsb879","article-title":"Translocation of botulinum neurotoxin light chain protease through the heavy chain channel","volume":"10","author":"Koriazova","year":"2003","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.neuro.2016.12.008_bib0100","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2133.2010.10085.x","article-title":"Long-term efficacy and respective potencies of botulinum toxin A and B: a randomized double-blind study","volume":"164","author":"Kranz","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.neuro.2016.12.008_bib0105","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/mus.22210","article-title":"Botulinum toxin-induced focal paresis in mice is unaffected by muscle activity","volume":"44","author":"Kutschenko","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.neuro.2016.12.008_bib0110","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jneumeth.2011.12.019","article-title":"Accurate quantification of tetanus neurotoxin-induced focal spasticity in mice using complex running wheels","volume":"205","author":"Kutschenko","year":"2012","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neuro.2016.12.008_bib0115","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.neulet.2016.06.001","article-title":"In vivo comparison of the neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA","volume":"627","author":"Kutschenko","year":"2016","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuro.2016.12.008_bib0120","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00415-009-0085-1","article-title":"Long-lasting benefits of botulinum toxin type B in Parkinson\u2019s disease-related drooling","volume":"256","author":"Lagalla","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.neuro.2016.12.008_bib0125","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1242\/jcs.112.16.2715","article-title":"Functional characterization of tetanus and botulinum neurotoxins binding domains","volume":"112","author":"Lalli","year":"1999","journal-title":"J. Cell. Sci."},{"key":"10.1016\/j.neuro.2016.12.008_bib0130","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/WNF.0b013e3181914d0a","article-title":"Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?","volume":"332","author":"Lange","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuro.2016.12.008_bib0135","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/0306-4522(94)90528-2","article-title":"Synaptotagmin I is present mainly in autonomic and sensory neurons of the rat peripheral nervous system","volume":"63","author":"Li","year":"1994","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuro.2016.12.008_bib0140","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.expneurol.2006.05.032","article-title":"Effects of commissural de- and remyelination on motor skill behavior in the cuprizone mouse model of multiple sclerosis","volume":"202","author":"Liebetanz","year":"2006","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuro.2016.12.008_bib0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2007.01.030","article-title":"A highly sensitive automated complex running wheel test to detect latent motor deficits in the mouse MPTP model of Parkinson\u2019s disease","volume":"205","author":"Liebetanz","year":"2007","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuro.2016.12.008_bib0150","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.febslet.2006.02.074","article-title":"The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves","volume":"580","author":"Mahrhold","year":"2006","journal-title":"FEBS. Lett."},{"key":"10.1016\/j.neuro.2016.12.008_bib0155","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1042\/BCJ20160439","article-title":"Only the complex N559-glycan in SV2C mediates high affinity binding to botulinum neurotoxin serotype A1","volume":"473","author":"Mahrhold","year":"2016","journal-title":"Biochem. J."},{"key":"10.1016\/j.neuro.2016.12.008_bib0160","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.coph.2004.12.006","article-title":"Botulinal neurotoxins: revival of an old killer","volume":"5","author":"Montecucco","year":"2005","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuro.2016.12.008_bib0165","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbrc.2009.01.037","article-title":"The N-terminal half of the receptor domain of botulinum neurotoxin A binds to microdomains of the plasma membrane","volume":"380","author":"Muraro","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuro.2016.12.008_bib0170","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.toxicon.2012.10.020","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders","volume":"67","author":"Naumann","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.neuro.2016.12.008_bib0175","doi-asserted-by":"crossref","first-page":"10498","DOI":"10.1016\/S0021-9258(17)34087-5","article-title":"Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes","volume":"269","author":"Nishiki","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuro.2016.12.008_bib0180","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0014-5793(95)01471-3","article-title":"The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b\/GD1a","volume":"378","author":"Nishiki","year":"1996","journal-title":"FEBS. Lett."},{"key":"10.1016\/j.neuro.2016.12.008_bib0185","doi-asserted-by":"crossref","first-page":"13493","DOI":"10.1523\/JNEUROSCI.3519-06.2006","article-title":"Synaptotagmin-2 is essential for survival and contributes to Ca2+ triggering of neurotransmittet release in central and neuromuscular synapses","volume":"26","author":"Pang","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuro.2016.12.008_bib0190","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1006\/taap.1994.1181","article-title":"Measurement of botulinum toxin activity: evaluation of the lethality assay","volume":"128","author":"Pearce","year":"1994","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.neuro.2016.12.008_bib0195","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1242\/jcs.103564","article-title":"Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins","volume":"125","author":"Peng","year":"2012","journal-title":"J. Cell. Sci."},{"key":"10.1016\/j.neuro.2016.12.008_bib0200","doi-asserted-by":"crossref","first-page":"e1004177","DOI":"10.1371\/journal.ppat.1004177","article-title":"Widespread sequence variations in VAMP-1 across vertebrates suggest a potential selective pressure from botulinum neurotoxins","volume":"10","author":"Peng","year":"2014","journal-title":"PLoS. Pathog."},{"key":"10.1016\/j.neuro.2016.12.008_bib0205","first-page":"493","article-title":"A simple method of estimating 50% endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Hyg."},{"key":"10.1016\/j.neuro.2016.12.008_bib0210","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrmicro3295","article-title":"Botulinum neurotoxins: genetic, structural and mechanistic insights","volume":"12","author":"Rossetto","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.neuro.2016.12.008_bib0215","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1365-2958.2003.03872.x","article-title":"The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction","volume":"51","author":"Rummel","year":"2004","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.neuro.2016.12.008_bib0220","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1073\/pnas.0609713104","article-title":"Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept","volume":"104","author":"Rummel","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuro.2016.12.008_bib0225","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1111\/j.1742-4658.2011.08196.x","article-title":"Exchange of the HCC domain mediating double receptor recognition improves the pharmacodynamic properties of botulinum neurotoxin","volume":"278","author":"Rummel","year":"2011","journal-title":"FEBS. J."},{"key":"10.1016\/j.neuro.2016.12.008_bib0230","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.toxicon.2015.09.009","article-title":"The long journey of botulinum neurotoxins into the synapse","volume":"1076","author":"Rummel","year":"2015","journal-title":"Toxicon"},{"issue":"Dec 1","key":"10.1016\/j.neuro.2016.12.008_bib0235","article-title":"Two feet on the membrane: uptake of clostridial neurotoxins","author":"Rummel","year":"2016","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.neuro.2016.12.008_bib0240","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0140-6736(90)90263-5","article-title":"Dose standardization of botulinum toxin","volume":"335","author":"Schantz","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.neuro.2016.12.008_bib0245","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/359832a0","article-title":"Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin","volume":"359","author":"Schiavo","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.neuro.2016.12.008_bib0250","first-page":"179","article-title":"Persistence of botulinum neurotoxin inactivation of nerve function","volume":"364","author":"Shoemaker","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.neuro.2016.12.008_bib0255","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1432-1033.1985.tb09070.x","article-title":"Inactivation of Clostridium botulinum type A neurotoxin by trypsin and purification of two tryptic fragments. Proteolytic action near the COOH-terminus of the heavy subunit destroys toxin-binding activity","volume":"151","author":"Shone","year":"1985","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.neuro.2016.12.008_bib0260","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.49.1.189","article-title":"Human response to botulinum toxin injection: type B compared with type A","volume":"49","author":"Sloop","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.neuro.2016.12.008_bib0265","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.febslet.2011.12.037","article-title":"Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: increased therapeutic dosage and immunogenicity","volume":"586","author":"Strotmeier","year":"2012","journal-title":"FEBS. Lett."},{"key":"10.1016\/j.neuro.2016.12.008_bib0270","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.cell.2006.10.030","article-title":"Molecular anatomy of a trafficking organelle","volume":"127","author":"Takamori","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.neuro.2016.12.008_bib0275","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1212\/01.wnl.0000174433.76707.8c","article-title":"Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial","volume":"65","author":"Tintner","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.neuro.2016.12.008_bib0280","doi-asserted-by":"crossref","first-page":"16993","DOI":"10.1074\/jbc.M710442200","article-title":"Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics","volume":"283","author":"Wang","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuro.2016.12.008_bib0285","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1042\/BJ20120100","article-title":"Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B","volume":"444","author":"Wang","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.neuro.2016.12.008_bib0290","doi-asserted-by":"crossref","first-page":"5035","DOI":"10.1096\/fj.12-210112","article-title":"Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distsinct sites of neuroparalysis","volume":"26","author":"Wang","year":"2012","journal-title":"FASEB J."},{"key":"10.1016\/j.neuro.2016.12.008_bib0295","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1468-1331.2006.01650.x","article-title":"Clinical value of botulinum toxin in neurological indications","volume":"13","author":"Ward","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.neuro.2016.12.008_bib0300","doi-asserted-by":"crossref","first-page":"5035","DOI":"10.3390\/toxins7124861","article-title":"Generation and Characterization of six recombinant botulinum neurotoxins as reference material to serve in an international proficiency test","volume":"7","author":"Weisemann","year":"2015","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.neuro.2016.12.008_bib0305","doi-asserted-by":"crossref","first-page":"E154","DOI":"10.3390\/toxins8050154","article-title":"Botulinum neurotoxin serotype A recognizes ist protein receptor SV2 by a different mechanism than botulinum neurotoxin B synaptotagmin","volume":"8","author":"Weisemann","year":"2016","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.neuro.2016.12.008_bib0310","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/s-0028-1112115","article-title":"Successful treatment of drooling in children with neurological disorders with botulinum toxin A or B","volume":"39","author":"Wilken","year":"2008","journal-title":"Neuropediatrics"},{"issue":"7","key":"10.1016\/j.neuro.2016.12.008_bib0315","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nsmb.3245","article-title":"N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A","volume":"23","author":"Yao","year":"2016","journal-title":"Nat. Struct. Mol. Biol."}],"container-title":["NeuroToxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161813X16302601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161813X16302601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T09:04:37Z","timestamp":1658307877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161813X16302601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":63,"alternative-id":["S0161813X16302601"],"URL":"https:\/\/doi.org\/10.1016\/j.neuro.2016.12.008","relation":{},"ISSN":["0161-813X"],"issn-type":[{"value":"0161-813X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BoNT\/AB hybrid maintains similar duration of paresis as BoNT\/A wild-type in murine running wheel assay","name":"articletitle","label":"Article Title"},{"value":"NeuroToxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuro.2016.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}